Literature DB >> 12723850

A study of treatment outcomes from atypical antipsychotic medications in the Virginia public system of community care.

David M Ziegler1, Thomas J Peachey.   

Abstract

This retrospective study examines treatment outcomes associated with atypical antipsychotic medications in areas of 1) treatment response; 2) employment; 3) living arrangements; and 4) hospitalization rates. The study included a random sample of adults with serious mental illness, who participated in treatment for at least 36 months. Study results suggest that the utilization of these medications, despite higher costs, promote cost savings of public dollars through reduced hospitalization and enhanced functioning/outcomes. The study results proved to be very vital to the Virginia State Legislature and key system policy makers and funding authorities, as important actions were taken to enhance consumer access to these important medications and essential services.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12723850     DOI: 10.1023/a:1022618922208

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  21 in total

1.  Ethical and clinical considerations in selecting patients who will receive clozapine.

Authors:  A L Pelonero; R L Elliott
Journal:  Hosp Community Psychiatry       Date:  1990-08

2.  Use patterns for antipsychotic medications in medicaid patients with schizophrenia.

Authors:  J S McCombs; M B Nichol; G L Stimmel; J Shi; R R Smith
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

3.  Schizophrenia: its etiology and impact.

Authors:  D D Miller
Journal:  Pharmacotherapy       Date:  1996 Jan-Feb       Impact factor: 4.705

Review 4.  Compliance with medication regimens for mental and physical disorders.

Authors:  J A Cramer; R Rosenheck
Journal:  Psychiatr Serv       Date:  1998-02       Impact factor: 3.084

Review 5.  Olanzapine. A pharmacoeconomic review of its use in schizophrenia.

Authors:  R H Foster; K L Goa
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

Review 6.  The evaluation and treatment of first-episode psychosis.

Authors:  B B Sheitman; H Lee; R Strous; R Strauss; J A Lieberman
Journal:  Schizophr Bull       Date:  1997       Impact factor: 9.306

7.  Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.

Authors:  G D Tollefson; T M Sanger; Y Lu; M E Thieme
Journal:  Arch Gen Psychiatry       Date:  1998-03

8.  Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

Authors:  A F Lehman; D M Steinwachs
Journal:  Schizophr Bull       Date:  1998       Impact factor: 9.306

Review 9.  Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.

Authors:  W M Glazer; B M Johnstone
Journal:  J Clin Psychiatry       Date:  1997       Impact factor: 4.384

10.  Experience with clozapine in a community mental health care setting.

Authors:  J C Connelly; J Fullick
Journal:  South Med J       Date:  1998-09       Impact factor: 0.954

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.